Breaking News

Financial Reports: Gilead

By Gil Roth | February 5, 2014

Stribild, Complera/Eviplera drive growth

Gilead 4Q13

4Q Revenues: $3.1 billion (+21%)

4Q Earnings: $791 million (+4%)

FY Revenues: $11.2 billion (+15%)

FY Earnings: $3.1 billion (+19%)

Comments: Product sales rose 21% in 4Q to $3.0 billion, driven by Stribild (+409% to $204 million), and Complera/Eviplera (+122% to $262 million). Atripla sales rose 2% to $934 million. In FY13, Atripla sales were up 2% to $3.6 billion, while Stribild posted $539 million (+837%) and Complera/Eviplera had $809 million in revenues (+137%). Gilead's cardiovascular franchise posted 24% gains in FY, with Letairis posting $520 million in sales (+27%) and Ranexa adding $449 million (+20%).
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.